Stratification of the biologic aggressiveness of non-small cell lung cancer using DNA flow cytometry and immunohistochemistry for the retinoblastoma protein

Lung Cancer

Volumn 45, Issue 3, 2004, Pages 307-316

  Otsuka, Hiroshi ^a   Funai, Sadao ^a   Tanaka, Akira ^a   Hara, Satoshi ^a   Shiozaki, Hitoshi ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

DNA ploidy; Flow cytometry; Immunohistochemistry; Lung cancer; Retinoblastoma protein; S phase fraction

Indexed keywords

DNA; GENE PRODUCT; RETINOBLASTOMA PROTEIN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER THERAPY; CELL CYCLE S PHASE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FLOW CYTOMETRY; GROWTH RATE; HISTOGRAM; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; LUNG SURGERY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PLOIDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECURRENT CANCER; RISK ASSESSMENT; STRATIFICATION; SURGICAL TECHNIQUE; TUMOR SUPPRESSOR GENE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DNA, NEOPLASM; FEMALE; FLOW CYTOMETRY; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PLOIDIES; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETINOBLASTOMA PROTEIN; TUMOR MARKERS, BIOLOGICAL;

EID: 3843054770     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2004.02.022     Document Type: Article

References (47)

1. Health and Welfare Statistics Association. Journal of health and welfare statistics, vol. 50, No. 9. Tokyo: Health and Welfare Statistics Association; 2003. p. 44-56.
2. Naruke T., Tsuchiya R., Kondo H., Asamura H. Prognosis and survival after resection for bronchogenic carcinoma based on the 1997 TNM-staging classification: the Japanese experience. Ann. Thorac. Surg. 71:2001;1759-1764
3. Ross J.S. DNA ploidy and cell cycle analysis in cancer diagnosis and prognosis. Oncology. 10:1996;867-887
4. Merkel D.E., McGuire W.L. Ploidy, proliferative activity and prognosis. DNA flow cytometry of solid tumors. Cancer. 65:1990;1194-1205
5. Steel G.G. Cell loss as a factor in the growth rate of human tumours. Eur. J. Cancer. 3:1967;381-387
6. Steel GG, Growth kinetics of tumours. Oxford: Clarendon Press; 1977.
7. Knudson A.G. Cancer genetics. Am. J. Med. Genet. 111:2002;96-102
8. Sherr C.J. The Pezcoller lecture: cancer cell cycles revisited. Cancer Res. 60:2000;3689-3695
9. Dryja T.P., Rapaport J.M., Joyce J.M., Petersen R.A. Molecular detection of deletions involving band q14 of chromosome 13 in retinoblastomas. Proc. Natl. Acad. Sci. U.S.A. 83:1986;7391-7394
10. Friend S.H., Bernards R., Rogelj S., et al. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature. 323:1986;643-646
11. Sherr C.J., McCormick F. The RB and p53 pathways in cancer. Cancer Cell. 2:2002;103-112
12. Kaye F.J. RB and cyclin dependent kinase pathways: defining a distinction between RB and p16 loss in lung cancer. Oncogene. 21:2002;6908-6914
13. Salgia R., Skarin A.T. Molecular abnormalities in lung cancer. J. Clin. Oncol. 16:1998;1207-1217
14. Sekido Y., Fong K.M., Minna J.D. Progress in understanding the molecular pathogenesis of human lung cancer. Biochim. Biophys. Acta. 1378:1998;F21-59
15. World Health Organization. Histological typing of lung tumours. 2nd ed. International Histological Classification of Tumors, No 1. Geneva: World Health Organization; 1981.
16. Mountain C.F. Revisions in the international system for staging lung cancer. Chest. 111:1997;1710-1717
17. International Union Against Cancer. Lung and Pleural Tumors. In: TNM classification of malignant tumors. 5th ed. New York: Wiley; 1997.
18. Shankey T.V., Rabinovitch P.S., Bagwell B., et al. Guidelines for implementation of clinical DNA Cytometry. Cytometry. 14:1993;472-477
19. Leers M.P.G., Theunissen P.H.M.H., Schutte B., Ramaekers F.C.S. Bivariate cytokeratin/DNA flow cytometric analysis of paraffin-embedded samples from colorectal carcinomas. Cytometry. 21:1995;101-107
20. Glogovac J.K., Porter P.L., Banker D.E., Rabinovitch P.S. Cytokeratin labeling of breast cancer cells extracted from paraffin-embedded tissue for bivariate flow cytometric analysis. Cytometry. 24:1996;260-267
21. Teodori L., Trinca M.L., Goehde W., et al. Cytokinetic investigation of lung tumors using the anti-bromodeoxyuridine (BUdR) monoclonal antibody method: comparison with DNA flow cytometric data. Int. J. Cancer. 45:1990;995-1001
22. Blomqvist C., Huuhtanen R., Pan Y., et al. Growth rate of lung metastases and S-phase fraction as determined by flow cytometry from the primary tumour in 25 patients with bone or soft-tissue sarcomas. Br. J. Cancer. 73:1996;1556-1559
23. Hofmann H.S., Knolle J., Bahn H., et al. Flow cytometric analysis of DNA content and proliferation and immunohistochemical staining of Ki-67 in non-small cell lung cancer. J. Cardiovasc. Surg. 42:2001;555-560
24. Ikonen J.T., Ojala A., Salenius J.P., et al. DNA flow cytometry in surgically treated lung cancer. Scand. Cardiovasc. J. 33:1999;228-233
25. Dalquen P., Moch H., Feichter G., et al. DNA aneuploidy, S-phase fraction, nuclear p53 positivity, and survival in non-small-cell lung carcinoma. Virchows Arch. 431:1997;173-179
26. Costa A., Silvestrini R., Mochen C., et al. P53 expression, DNA ploidy and S-phase cell fraction in operable locally advanced non-small cell lung cancer. Br. J. Cancer. 73:1996;914-919
27. Visakorpi T., Holli K., Hakama M. High cell proliferation activity determined by DNA flow cytometry and prognosis in epidermoid lung carcinoma. Acta Oncol. 34:1995;605-609
28. Volm M., Drings P., Mattern J., et al. Prognostic significance of DNA patterns and resistance-predictive tests in non-small cell lung carcinoma. Cancer. 56:1985;1396-1403
29. Hedley D.W. Flow cytometry using paraffin-embedded tissue: five years on. Cytometry. 10:1989;229-241
30. Xu H.J., Hu S.X., Cagle P.T., et al. Absence of retinoblastoma protein expression in primary non-small cell lung carcinomas. Cancer Res. 51:1991;2735-2739
31. Benedict W.F., Xu H.J., Hu S.X., Takahashi R. Role of the retinoblastoma gene in the initiation and progression of human cancer. J. Clin. Invest. 85:1990;988-993
32. Gorgoulis V.G., Zacharatos P., Kotsinas A., et al. Altered expression of the cell cycle regulatory molecules pRb, p53 and MDM2 exert a synergetic effect on tumor growth and chromosomal instability in non-small cell lung carcinomas (NSCLCs). Mol. Med. 6:2000;208-237. [Erratum in: Mol Med 2001;7:861]
33. INK4A and cyclin D1 in non-small cell lung carcinoma and their clinical significance. J. Pathol. 188:1999;351-360
34. D'Amico T.A., Massey M., Herndon J.E. II, et al. A biological risk model for stage I lung cancer: immunohistochemical analysis of 408 patients with the use of ten molecular markers. J. Thorac. Cardiovasc. Surg. 117:1999;736-743
35. ink4a, and p53 expression with 3p loss of heterozygosity, other genetic abnormalities, and clinical features in 103 primary non-small cell lung cancers. Clin. Cancer Res. 5:1999;791-800
36. Muguerza J.M., Diez M., Torres A.J., et al. Prognostic value of flow cytometric DNA analysis in non-small-cell lung cancer: Rationale of sequential processing of frozen and paraffin-embedded tissue. World J. Surg. 21:1997;323-329
37. Sahin A.A., Ro J.Y., El-Naggar A.K., et al. Flow cytometric analysis of the DNA content of non-small cell lung cancer. Cancer. 65:1990;530-537
38. Volm M., Hahn E.W., Mattern J., et al. Five-year follow-up study of independent clinical and flow cytometric prognostic factors for the survival of patients with non-small cell lung carcinoma. Cancer Res. 48:1988;2923-2928
39. Tinnemans M.M.F.J., Schutte B., Lenders M.H.J.H., et al. Cytokinetic analysis of lung cancer by in vivo bromodeoxyuridine labeling. Br. J. Cancer. 67:1993;1217-1222
40. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995;311:899-909.
41. Stal O., Skoog L., Rutqvist L.E., et al. S-phase fraction and survival benefit from adjuvant chemotherapy or radiotherapy of breast cancer. Br. J. Cancer. 70:1994;1258-1262
42. Yu J., Shaeffer J., Zhu A., et al. Flow cytometric DNA content and clinical outcome in patients with non-small cell lung cancer given postoperative radiation therapy. Cytometry. 14:1993;428-432
43. Abe S., Tsuneta Y., Makimura S., et al. Nuclear DNA content as an indicator of chemosensitivity in small-call carcinoma of the lung. Anal. Quant. Cytol. Histol. 9:1987;425-428
44. Volm M., Drings P., Mattern J., et al. Relevance of DNA-fluorimetry and short-term resistance testing for adjuvant treatment of non-small cell lung carcinomas. Anticancer Res. 6:1986;931-934
45. Gregorc V., Ludovini V., Pistola L., et al. Relevance of p53, bcl-2 and Rb expression on resistance to cisplatin-based chemotherapy in advanced non-small cell lung cancer. Lung Cancer. 39:2003;41-48
46. Ojala A., Kallioniemi O.P., Wigren T., et al. Flow cytometric analysis of tumour DNA profile related to response to radiotherapy and survival in inoperable lung cancer. Acta Oncol. 29:1990;983-988
47. Volm M., Efferth T. Relationship of DNA ploidy to chemoresistance of tumors as measured by in vitro tests. Cytometry. 11:1990;406-410